Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 11/20 | 0.45 |
| ▸ | PPARG | P37231 | 10/20 | 0.45 |
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.43 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 4/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5100830 | 0.92 | PPARA (0.53) | PPARAPPARGCYSLTR2CYSLTR1PPARD | |
| SCHEMBL5101243 | 0.89 | MAPT (0.46) | PPARAPPARGTSHRCYSLTR2CYSLTR1 | |
| SCHEMBL5100738 | 0.84 | MAPT (0.45) | PPARAPPARGTSHRCYSLTR2CYSLTR1 | |
| SCHEMBL5100255 | 0.82 | MAPT (0.51) | PPARAPPARGLMNAMAPTRXFP1 | |
| SCHEMBL5113340 | 0.80 | PPARG (0.49) | PPARAPPARGTSHRCYSLTR2CYSLTR1 | |
| SCHEMBL5103845 | 0.77 | MAPT (0.41) | PPARAPPARGTSHRCYSLTR2CYSLTR1 | |
| SCHEMBL5104081 | 0.76 | PPARG (0.55) | PPARAPPARG | |
| SCHEMBL5112766 | 0.75 | PPARG (0.49) | PPARAPPARGTSHRCYSLTR2CYSLTR1 | |
| SCHEMBL5104269 | 0.75 | PPARG (0.45) | PPARAPPARGTSHRLMNAMAPT | |
| SCHEMBL5443755 | 0.75 | TSHR (0.48) | PPARAPPARGTSHRCYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6809095-B2 | NOVEL ANTITOBESITY AND HYPOCHOLESTEROLEMIC COMPOUNDS LOWER TOTAL CHOLESTEROL; INCREASE HIGH DENSITY LIPOPROTEIN (HDL) AND DECREASE LOW DENSTIY LIPOPROTEIN | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-10-26 | — | — | US | claimed |
| JP-2002543194-A | — | — | 2002-12-17 | — | — | JP | claimed |
| US-20020082258-A1 | Novel bicyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION & REDDY- CHEMINOR, INC. | 2002-06-27 | — | — | US | claimed |
| EP-1175412-A1 | SUBSTITUTED BICYCLIC HETEROCYCLES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTIOBESITY AND HYPOCHOLESTEROLEMIC AGENTS | Dr. Reddy's Research Foundation (IN) | 2002-01-30 | — | — | EP | claimed |
| US-20010051619-A1 | Novel bicyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION AND REDDY-CHEMINOR, INC. | 2001-12-13 | — | — | US | claimed |
| US-6265401-B1 | ANTIDIABETIC AGENTS | REDDY-CHEMINOR, INC. | 2001-07-24 | — | — | US | claimed |
| EP-1082313-A1 | BICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2001-03-14 | — | — | EP | claimed |
| WO-2000066572-A1 | SUBSTITUTED BICYCLIC HETEROCYCLES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTIOBESITY AND HYPOCHOLESTEROLEMIC AGENTS | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-11-09 | — | — | WO | claimed |
| WO-1999020614-A1 | BICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1999-04-29 | — | — | WO | claimed |
| US-7348426-B1 | Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents | DR. REDDY'S LABORATIES LIMITED (IN) | 2008-03-25 | — | — | US | disclosed |
| US-7348426-B1 | Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents | DR. REDDY'S LABORATIES LIMITED (IN) | 2008-03-25 | — | — | US | disclosed |
| US-6846824-B2 | Bicyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-01-25 | — | — | US | disclosed |
| US-6809095-B2 | NOVEL ANTITOBESITY AND HYPOCHOLESTEROLEMIC COMPOUNDS LOWER TOTAL CHOLESTEROL; INCREASE HIGH DENSITY LIPOPROTEIN (HDL) AND DECREASE LOW DENSTIY LIPOPROTEIN | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-10-26 | — | — | US | disclosed |
| US-20020082258-A1 | Novel bicyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION & REDDY- CHEMINOR, INC. | 2002-06-27 | — | — | US | disclosed |
| EP-1175412-A1 | SUBSTITUTED BICYCLIC HETEROCYCLES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTIOBESITY AND HYPOCHOLESTEROLEMIC AGENTS | Dr. Reddy's Research Foundation (IN) | 2002-01-30 | — | — | EP | disclosed |
| US-20010051619-A1 | Novel bicyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION AND REDDY-CHEMINOR, INC. | 2001-12-13 | — | — | US | disclosed |
| US-6265401-B1 | ANTIDIABETIC AGENTS | REDDY-CHEMINOR, INC. | 2001-07-24 | — | — | US | disclosed |
| EP-1082313-A1 | BICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2001-03-14 | — | — | EP | disclosed |
| WO-2000066572-A1 | SUBSTITUTED BICYCLIC HETEROCYCLES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTIOBESITY AND HYPOCHOLESTEROLEMIC AGENTS | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-11-09 | — | — | WO | disclosed |
| WO-1999020614-A1 | BICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051619-A1 | Novel bicyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | CPT1A, GPR119, SLC5A1 | PPARA 232/4885PPARG 158/4885TSHR 2573/4885 |
| US-20020082258-A1 | Novel bicyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | SLC5A1, CYP11B1, CYP4A11 | PPARA 884/4885PPARG 618/4885TSHR 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.